Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22


Drug candidates in clinical trials for Alzheimer's disease.

Hung SY, Fu WM.

J Biomed Sci. 2017 Jul 19;24(1):47. doi: 10.1186/s12929-017-0355-7. Review.


Nicotinic acetylcholine receptor-mediated protection of the rat heart exposed to ischemia reperfusion.

Mavropoulos SA, Khan NS, Levy ACJ, Faliks BT, Sison CP, Pavlov VA, Zhang Y, Ojamaa K.

Mol Med. 2017 Jun 8;23. doi: 10.2119/molmed.2017.00091. [Epub ahead of print]


Prediction of tissue-specific effects of gene knockout on apoptosis in different anatomical structures of human brain.

Petrovskiy ED, Saik OV, Tiys ES, Lavrik IN, Kolchanov NA, Ivanisenko VA.

BMC Genomics. 2015;16 Suppl 13:S3. doi: 10.1186/1471-2164-16-S13-S3. Epub 2015 Dec 16.


Forebrain-Cerebellar Interactions During Learning.

Weiss C, Weible AP, Galvez R, Disterhoft JF.

Cellscience. 2006 Oct;3(2):200-230. Epub 2006 Oct 27.


Pharmacological investigations of new galantamine peptide esters.

Tsvetkova D, Danchev N, Nikolova I, Obreshkova D.

Biotechnol Biotechnol Equip. 2014 Jan 2;28(1):160-163.


The use of medications approved for Alzheimer's disease in autism spectrum disorder: a systematic review.

Rossignol DA, Frye RE.

Front Pediatr. 2014 Aug 22;2:87. doi: 10.3389/fped.2014.00087. eCollection 2014. Review.


Why trace and delay conditioning are sometimes (but not always) hippocampal dependent: a computational model.

Moustafa AA, Wufong E, Servatius RJ, Pang KC, Gluck MA, Myers CE.

Brain Res. 2013 Feb 1;1493:48-67. doi: 10.1016/j.brainres.2012.11.020. Epub 2012 Nov 23.


A novel neurotrophic drug for cognitive enhancement and Alzheimer's disease.

Chen Q, Prior M, Dargusch R, Roberts A, Riek R, Eichmann C, Chiruta C, Akaishi T, Abe K, Maher P, Schubert D.

PLoS One. 2011;6(12):e27865. doi: 10.1371/journal.pone.0027865. Epub 2011 Dec 14.


Galantamine counteracts development of learning impairment in guinea pigs exposed to the organophosphorus poison soman: clinical significance.

Mamczarz J, Kulkarni GS, Pereira EF, Albuquerque EX.

Neurotoxicology. 2011 Dec;32(6):785-98. doi: 10.1016/j.neuro.2011.07.001. Epub 2011 Jul 19.


Age sensitivity of behavioral tests and brain substrates of normal aging in mice.

Kennard JA, Woodruff-Pak DS.

Front Aging Neurosci. 2011 May 25;3:9. doi: 10.3389/fnagi.2011.00009. eCollection 2011.


The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice.

Wilkinson DS, Gould TJ.

Behav Brain Res. 2011 Sep 30;223(1):53-7. doi: 10.1016/j.bbr.2011.04.010. Epub 2011 Apr 14.


Total synthesis of (+)-complanadine A using an iridium-catalyzed pyridine C-H functionalization.

Fischer DF, Sarpong R.

J Am Chem Soc. 2010 May 5;132(17):5926-7. doi: 10.1021/ja101893b.


Young and older good learners have higher levels of brain nicotinic receptor binding.

Woodruff-Pak DS, Lehr MA, Li JG, Liu-Chen LY.

Neurobiol Aging. 2010 Jun;31(6):1032-43. doi: 10.1016/j.neurobiolaging.2008.09.002. Epub 2008 Oct 23.


Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro.

Reid RT, Sabbagh MN.

J Neural Transm (Vienna). 2008 Oct;115(10):1437-44. doi: 10.1007/s00702-008-0107-7. Epub 2008 Aug 26.


Effects of paradigm and inter-stimulus interval on age differences in eyeblink classical conditioning in rabbits.

Woodruff-Pak DS, Seta SE, Roker LA, Lehr MA.

Learn Mem. 2007 Apr 6;14(4):287-94. Print 2007 Apr.


Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen.

Thavichachart N, Phanthumchinda K, Chankrachang S, Praditsuwan R, Nidhinandana S, Senanarong V, Poungvarin N.

Int J Clin Pract. 2006 May;60(5):533-40.


Supplemental Content

Support Center